Markt oder Branche auswählen:
Chart-Typ:
Zeitraum:
| Dividendenbekanntmachungen (04.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1ST SOURCE CORPORATION US3369011032 0,4 USD 0,3472 EUR ALCOA CORPORATION US0138721065 0,1 USD 0,0868 EUR ARCA CONTINENTAL SAB DE... ► Artikel lesen |
| Dividendenbekanntmachungen (30.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACOMO NV NL0000313286 - 0,45 EUR BANK OF MONTREAL CA0636711016 1,63 CAD 1,0252 EUR CONAGRA BRANDS INC US2058871029 0,35 USD 0... ► Artikel lesen |
| Takeda Announces US Availability Of GAMMAGARD LIQUID ERC For Primary Immunodeficiency Treatment | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK), Thursday announced the U.S. availability of GAMMAGARD LIQUID ERC, which is approved as a replacement therapy for people two years... ► Artikel lesen |
| Halozyme Therapeutics, Inc.: Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE | Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab
SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics... ► Artikel lesen |
| Takeda Pharmaceutical, Protagonist Therapeutics Announces Submission Of NDA For Rusfertide | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX), Monday announced the submission of a New Drug Application regarding rusfertide for the... ► Artikel lesen |
| XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab | - Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine... ► Artikel lesen |
| Takeda Canada: British Columbia Now Reimburses FRUZAQLA | TOKYO (dpa-AFX) - Takeda Canada announced that FRUZAQLA - fruquintinib capsules - will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer... ► Artikel lesen |
| Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera | TOKYO (dpa-AFX) - Protagonist Therapeutics, Inc. (PTGX) and Takeda (TAK) announced new 52-week results from the pivotal Phase 3 VERIFY study of rusfertide in patients with polycythemia vera... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .